A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Launched by ABBVIE · Jun 16, 2020
Trial Information
Current as of May 10, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.
- • Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the Psoriasis Area and Severity Index (PASI) and Static Physician Global Assessment (sPGA).
- • Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.
- Exclusion Criteria:
- • - Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Fountain Valley, California, United States
Sacramento, California, United States
San Diego, California, United States
Fort Lauderdale, Florida, United States
Jacksonville, Florida, United States
Largo, Florida, United States
Tampa, Florida, United States
Darien, Illinois, United States
Rolling Meadows, Illinois, United States
Reno, Nevada, United States
Kew Gardens, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Mayfield Heights, Ohio, United States
Tulsa, Oklahoma, United States
Charleston, South Carolina, United States
Arlington, Texas, United States
Morgantown, West Virginia, United States
Kenosha, Wisconsin, United States
Milwaukee, Wisconsin, United States
Calgary, Alberta, Canada
St. John's, Newfoundland And Labrador, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Munster, Niedersachsen, Germany
Kiel, Schleswig Holstein, Germany
Bad Bentheim, , Germany
Bonn, , Germany
Dresden, , Germany
Mainz, , Germany
Nagoya Shi, Aichi, Japan
Tsu Shi, Mie, Japan
Hirakata Shi, Osaka, Japan
Shinjuku Ku, Tokyo, Japan
Lodz, Lodzkie, Poland
Lodz, Lodzkie, Poland
Warszawa, Mazowieckie, Poland
Rzeszow, Podkarpackie, Poland
Gdansk, Pomorskie, Poland
Esplugues De Llobregat, Barcelona, Spain
Madrid, , Spain
Madrid, , Spain
Madrid, , Spain
Pontevedra, , Spain
Exeter, Devon, United Kingdom
London, London, City Of, United Kingdom
Glasgow, Scotland, United Kingdom
Camberley, , United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Saint Petersburg, Florida, United States
London, London, City Of, United Kingdom
Munster, Niedersachsen, Germany
Exeter, Devon, United Kingdom
London, , United Kingdom
Sacramento, California, United States
Hiroshima Shi, Hiroshima, Japan
Itabashi Ku, Tokyo, Japan
Rzeszow, Podkarpackie, Poland
Fountain Valley, California, United States
Tampa, Florida, United States
San Diego, California, United States
Tampa, Florida, United States
Rolling Meadows, Illinois, United States
Mayfield Heights, Ohio, United States
Muenster, Nordrhein Westfalen, Germany
Camberley, Surrey, United Kingdom
Fountain Valley, California, United States
Reno, Nevada, United States
Kew Gardens, New York, United States
Mayfield Heights, Ohio, United States
Milwaukee, Wisconsin, United States
Calgary, Alberta, Canada
Bad Bentheim, Niedersachsen, Germany
Bonn, Nordrhein Westfalen, Germany
Mainz, Rheinland Pfalz, Germany
Dresden, Sachsen, Germany
Itabashi Ku, Tokyo, Japan
Exeter, Devon, United Kingdom
Plymouth, Devon, United Kingdom
London, Greater London, United Kingdom
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials